USE OF <sup>177</sup>Lu-PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER

Purpose of the study: to present current data regarding challenges in treatment castration-resistant prostate cancer (CRPC) and relationship between CRPC expression prostate-specific membrane antigen (psma). Material Methods. The search for relevant sources was carried out Pubmed, elibrary, Medline databases. review included 43 publications, most which were published over past 5 years. Results. Currently, (PC) is one common cancers men. Moreover, time, patients develop resistance therapy, significantly worsens prognosis disease. Psma molecular markers cancer; a number studies have demonstrated direct correlation level psma tumor grade, stage aggressiveness. Numerous indicate that represents an excellent target radionuclide therapy cancer. 68 Ga or 18 F-psma Pet/Ct method diagnosing PC. It should be noted modern trends development nuclear medicine are closely related theranostics; therefore, creation highly specific theranostic pairs diagnosis subsequent malignant tumors great significance. obtained 177 lu demonstrates optimal radiation physical characteristics therapeutic radionuclides, while psma-617 studied ligands therapy. Conclusion. there several covering with various psmacompounds labeled lu. Radionuclide lu-psma has been shown recommended metastatic CRPC, who no benefits from alternative therapies contraindications them.